Market Place
Sourcing Support
HilleVax Q3 2024 Financial Results & Recent Progress
07 Nov 2024 //
GLOBENEWSWIRE
HilleVax Reports Q2 2024 Results And Recent Progress
08 Aug 2024 //
GLOBENEWSWIRE
UniQure, Arbutus, HilleVax Announce Layoffs
01 Aug 2024 //
FIERCE BIOTECH
HilleVax Announces Reduction in Force
31 Jul 2024 //
GLOBENEWSWIRE
HilleVax stock sink 80% as Norovirus Vaccine flunks phase 2 trial in infants
08 Jul 2024 //
FIERCE BIOTECH
HilleVax Q1 2024 Financials And Company Progress Highlights
09 May 2024 //
GLOBENEWSWIRE
HilleVax Reports Full Year 2023 Financial Results
20 Mar 2024 //
GLOBENEWSWIRE
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05 Feb 2024 //
GLOBENEWSWIRE
HilleVax Announces Executive Management Appointment of Sean McLoughlin as COO
18 Jan 2024 //
GLOBENEWSWIRE
HilleVax and Kangh Announce Exclusive License Agreement
08 Jan 2024 //
GLOBENEWSWIRE
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
HilleVax Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
HilleVax to Present at Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Conference
26 Sep 2023 //
GLOBENEWSWIRE
HilleVax Announces Closing of Public Offering of Common Stock
25 Sep 2023 //
GLOBENEWSWIRE
HilleVax Announces Proposed Public Offering of Common Stock
19 Sep 2023 //
GLOBENEWSWIRE
HilleVax Announces Pricing of Public Offering of Common Stock
19 Sep 2023 //
GLOBENEWSWIRE
HilleVax Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
HilleVax delays PhIIb norovirus data until mid-2024 over processing logistics
14 Aug 2023 //
ENDPTS
HilleVax Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its BOD
09 May 2023 //
GLOBENEWSWIRE
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study
25 Apr 2023 //
GLOBENEWSWIRE
HilleVax Reports Full Year 2022 Financial Results
17 Mar 2023 //
GLOBENEWSWIRE
HilleVax Announces Executive Management Appointments and Promotions
09 Jan 2023 //
GLOBENEWSWIRE
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1
05 Dec 2022 //
GLOBENEWSWIRE
HilleVax Reports 3Q 2022 Financial Results & Highlights Recent Company Progress
10 Nov 2022 //
GLOBENEWSWIRE
HilleVax to Participate in November Investor Conferences
10 Nov 2022 //
GLOBENEWSWIRE
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
01 Sep 2022 //
PRESS RELEASE
HilleVax Announces Positive Recommendation from Safety Data Monitoring
31 Aug 2022 //
GLOBENEWSWIRE
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Forum
15 Aug 2022 //
PRESS RELEASE
HilleVax Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
PRESS RELEASE
Is HilleVax, Inc. (NASDAQ:HLVX) Popular Amongst Insiders?
02 Aug 2022 //
NASDAQ
HilleVax Announces Results from 5-Year Study on Long-Term Immunogenicity
20 Jul 2022 //
GLOBENEWSWIRE
Norovirus vaccine developer HilleVax stock jumps 23%
23 Jun 2022 //
SEEKING ALPHA
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
08 Jun 2022 //
PRESS RELEASE
HilleVax stock jumps 11% following four analyst buy ratings
24 May 2022 //
SEEKING ALPHA
HilleVax Announces Closing of IPO and Full Exercise of Underwriters Option
03 May 2022 //
GLOBENEWSWIRE
HilleVax Initiates PIIb Trial of HIL-214 Vaccine Candidate
02 May 2022 //
PRESS RELEASE
Two biotechs price their IPOs while another launches its Nasdaq bid
29 Apr 2022 //
ENDPTS
HilleVax Announces Pricing of Upsized Initial Public Offering
28 Apr 2022 //
GLOBENEWSWIRE
Two biotechs set out to end sector’s IPO drought
27 Apr 2022 //
BIOPHARMADIVE
